ORIGINAL ARTICLE |
|
Year : 2016 | Volume
: 8
| Issue : 2 | Page : 57-61 |
|
Female pattern hair loss: A retrospective study in a tertiary referral center
Tee Wei Siah1, Llorenia Muir-Green1, Jerry Shapiro2
1 Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC V5Z 4E8, Canada 2 Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC V5Z 4E8, Canada; Department of Dermatology, New York University Langone Medical Center, New York City, New York, USA
Correspondence Address:
Tee Wei Siah Royal Victoria Infirmary, Queen Victoria Road, Newcastle Upon Tyne NE1 4LP Canada
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0974-7753.188033
|
|
Background: Female pattern hair loss (FPHL) is a very common problem in women. The underlying pathophysiology remains unclear, and there are no universally agreed treatment guidelines. Objective: We explored the clinical features, relevant medical and family history, laboratory evaluation, and treatment and compliance of 210 patients with FPHL. Methods: Data analysis from case notes was performed on 210 patients with a diagnosis of FPHL seen from January 2011 to December 2011. Results: The youngest individual was 8 years old and the oldest was 86 years old. Nearly, 85% of the patients had a family history of androgenetic alopecia. Hypothyroidism and hypertension are the most common medical problems. Telogen effluvium (TE) is the most common concurrent hair loss condition. Only 38% of the patients were found to have normal Vitamin D level, 71% had ferritin level above 30 μg/L, and 85% had normal zinc level at the first consultation. Fifty-nine percent of the patients failed to attend any follow-up appointments. Limitations: One of the limitations of this study is its retrospective nature. Moreover, the severity of FPHL in terms of Ludwig score was not routinely documented in the medical charts. Conclusion: History of TE, hypothyroidism and hypertension, and low serum Vitamin D is common in our patients with FPHL. |
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|